Top Story

FDA approves Solosec oral granules for treatment of bacterial vaginosis

September 18, 2017

Symbiomix Therapeutics announced today that the FDA has approved Solosec 2-g oral granules as the first single-dose oral treatment option for adult women with bacterial vaginosis, the most common gynecologic infection in the U.S., according to a press release.

Solosec (secnidazole, Symbiomix) — a next-generation, 5-nitroimidazole antimicrobial agent — is the first oral antibiotic to be approved for bacterial vaginosis (BV) in more than a decade, according to David L. Stern, CEO of Symbiomix.

In the Journals

Early miscarriage potentially linked to influenza vaccination

September 14, 2017
Researchers discovered a potential link between miscarriage early in pregnancy and receipt of the influenza A(H1N1)pdm09-containing vaccine in the preceding 28 days…
In the Journals Plus

Surgeons greatly influence likelihood of contralateral prophylactic mastectomy

September 13, 2017
Women with breast cancer appeared three times more likely to undergo contralateral prophylactic mastectomy if their attending surgeon was less reluctant to perform the…
In the Journals PlusPerspective

Hormone therapy does not increase mortality risk in postmenopausal women

September 12, 2017
All-cause mortality and death rates from cardiovascular diseases, cancer and other causes do not significantly differ among women assigned to receive hormone therapy for…
More Headlines »